Drugs News and Research

RSS

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004

A simple urine sample could soon be used to predict the complex toxic effects of new drugs

BlueGnome has pioneered the use of statistical signal modelling in the analysis of high throughput experimental data. Its first product BlueFuse for Microarrays uses statistical modelling techniques to eliminate Œnoise‚ generated in microarray experiments, enabling researchers to automatically identify the presence or absence of genes and proteins with a higher level of confidence than is currently possible.

5 Apr 2004

Common cholinesterase inhibitor eases behavioral symptoms like agitation, depression, and psychosis in patients

The so-called "memory drugs" used to treat Alzheimer's disease and other causes of dementia also ease or prevent a barrage of troublesome behaviors that affect the majority of patients, ultimately lightening the burden on caregivers, researchers have found. They report their results in the March issue of the American Journal of Psychiatry.

5 Apr 2004

AMA advises physicians to order influenza vaccine

In order to ensure the availability of influenza vaccine for administration early this coming fall, the AMA recommends that physicians and providers begin to order supplies of influenza vaccine immediately. In 2003, large numbers of cases of influenza began to appear in October, and activity was widespread.

5 Apr 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004

Doctors Likelier to Delay Prescribing Antiretroviral Drugs for Women and Minority HIV Patients

A new UCLA study finds that doctors who follow guidelines recommending the delay of antiretroviral therapy for non-adherent HIV patients are likelier to put off that treatment for Latinos, women and poor patients than they do for others. In addition, doctors are slower to prescribe protease inhibitors for African American patients whether or not the physician follows the guidelines.

4 Apr 2004

New software promises to speed drug development

Researchers at Rensselaer Polytechnic Institute today announced the release of a software program capable of quickly identifying molecules that show promise for future medicines. The software program enables drug makers to comb through enormous databases of potential molecules and identify the ones that have sound medicinal properties.

3 Apr 2004

Compounds that may stop replication of T-cell leukemia virus

Researchers are analyzing several compounds that may inhibit the enzyme that is essential for the reproduction of the Human T-cell Leukemia Virus Type 1 (HTLV-I), which has infected 15 to 20 million people worldwide. The virus causes the fatal adult T-cell leukemia in up to 10 percent of those infected.

1 Apr 2004

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

In a study of Han Chinese patients, researchers have for the first time directly linked a gene of the immune system to a severe adverse drug reaction called Stevens-Johnson syndrome (SJS), according to a Duke University Medical Center medical geneticist and collaborators in Taiwan.

1 Apr 2004

Sheffield University pioneers osteoporosis research

A leading osteoporosis expert from Sheffield has been awarded the prestigious Society for Endocrinology Medal and the Kohn Foundation Award for his 25-year commitment to revolutionising the treatment and diagnosis of osteoporosis.

31 Mar 2004

How rat's genetic blueprint stacks up against those of mice and humans

An international research team, supported by the National Institutes of Health (NIH), today announced it has completed a high-quality, draft sequence of the genome of the laboratory rat, and has used that data to explore how the rat's genetic blueprint stacks up against those of mice and humans.

31 Mar 2004

DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology

Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.

31 Mar 2004

First patient dosed with Tesmilifene in pivotal breast cancer study

YM BioSciences Inc., the cancer drug development company, today announced that the first patient has been dosed in its 700 patient Phase III registration trial.

31 Mar 2004

Drug, Nembutal can suppress activity in colon cancer cells

A barbiturate once commonly used to treat anxiety may play a role in controlling the spread of colon cancer, say researchers from The University of Texas M. D. Anderson Cancer Center.

30 Mar 2004

Zebrafish show effects of ionizing and UV radiation differ during embryo development

Adam Dicker, M.D., Ph.D., associate professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University and Jefferson’s Kimmel Cancer Center in Philadelphia, Mary Frances McAleer, M.D., Ph.D., a resident in the Department of Radiation Oncology at Jefferson Medical College and their co-workers compared the effects on zebrafish embryos of two types of radiation – ionizing radiation, which is the kind given to patients for cancer treatment, and ultraviolet (UV) radiation, which comes naturally from the sun.

30 Mar 2004

Human Genome Sciences can begin cardiovascular disease research

Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.

30 Mar 2004

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen benefits for patients.

30 Mar 2004

Alzheimer’s Association asks for $40 million in additional funding

The Alzheimer’s Association today called on the House of Representatives to provide $40 million in additional funding this year to the National Institutes of Health NIH) to support large-scale clinical trials for treatments that would slow or delay the progression of Alzheimer’s disease.

30 Mar 2004

New Australian collaboration to discover new drugs targeting epilepsy and anxiety

Bionomics Limited and Southern Cross University announced today that they had established a collaboration to discover new drugs targeting epilepsy and anxiety. Under the arrangement, Southern Cross University will provide Bionomics with extracts from its collection of Australian-based natural products, together with expertise in natural products chemistry.

30 Mar 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004

Drugs News and Research

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

A simple urine sample could soon be used to predict the complex toxic effects of new drugs

Common cholinesterase inhibitor eases behavioral symptoms like agitation, depression, and psychosis in patients

AMA advises physicians to order influenza vaccine

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Doctors Likelier to Delay Prescribing Antiretroviral Drugs for Women and Minority HIV Patients

New software promises to speed drug development

Compounds that may stop replication of T-cell leukemia virus

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

Sheffield University pioneers osteoporosis research

How rat's genetic blueprint stacks up against those of mice and humans

DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology

First patient dosed with Tesmilifene in pivotal breast cancer study

Drug, Nembutal can suppress activity in colon cancer cells

Zebrafish show effects of ionizing and UV radiation differ during embryo development

Human Genome Sciences can begin cardiovascular disease research

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Alzheimer’s Association asks for $40 million in additional funding

New Australian collaboration to discover new drugs targeting epilepsy and anxiety

Enzyme called COX-2 may promote the development of ovarian tumors

Drug Discovery - Second Edition eBook

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News